Associated Papers
Physiological functions and pharmacological targeting of transient receptor potential channels.
Chubanov V et al.
Pharmacological Reviews, 2025
Erlotinib therapy for Olmsted syndrome with p.L655P missense mutation in the TRPV3 gene: a case report.
Zhang J et al.
Frontiers in Medicine, 2025
The cumulative effect of compound heterozygous variants in TRPV3 caused Olmsted syndrome.
Mo R et al.
Journal of Dermatological Science, 2024
Pathogenesis and management of TRPV3-related Olmsted syndrome.
Lu A et al.
Frontiers in Genetics, 2024
Structural basis of TRPV3 inhibition by an antagonist.
Fan J et al.
Nature Chemical Biology, 2023
Olmsted syndrome causing point mutants of TRPV3 (G568C and G568D) show defects in intracellular Ca2+-mobilization and induce lysosomal defects.
Jain A et al.
Biochemical and Biophysical Research Communications, 2022
Hair Loss Caused by Gain-of-Function Mutant TRPV3 Is Associated with Premature Differentiation of Follicular Keratinocytes.
Song Z et al.
The Journal of Investigative Dermatology, 2021
Genotype‒Phenotype Correlation of TRPV3-Related Olmsted Syndrome.
Zhong W et al.
The Journal of Investigative Dermatology, 2021
Pharmacological Inhibition of the Temperature-Sensitive and Ca2+-Permeable Transient Receptor Potential Vanilloid TRPV3 Channel by Natural Forsythoside B Attenuates Pruritus and Cytotoxicity of Keratinocytes.
Zhang H et al.
The Journal of Pharmacology and Experimental Therapeutics, 2019
Olmsted Syndrome Caused by a Heterozygous p.Gly568Val Missense Mutation in TRPV3 Gene.
Choi JY et al.
Yonsei Medical Journal, 2018
Identification of a heterozygous p.Gly568Val missense mutation in the TRPV3 gene in a Japanese patient with Olmsted syndrome: In silico analysis of TRPV3.
Nagai H et al.
The Journal of Dermatology, 2017
Expanding the Phenotypic Spectrum of Olmsted Syndrome.
Wilson NJ et al.
The Journal of Investigative Dermatology, 2015
Select a paper to view details